Brief: Elicera Therapeutics Q2 Operating Loss Widens To Sek 5.8 Mln
29/08/2024 07:34
Aug 29 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* Q2 LOSS FOR PERIOD AMOUNTED TO SEK -5,622,779 (-4,335,852)
* Q2 OPERATING PROFIT/LOSS AMOUNTED TO SEK -5,841,409 (-4
466 286)
Source text for Eikon: ID:nWkr4Pz75t
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent